How can pharma and medtech companies optimize their logistics processes faster and more cost-effectively without losing GDP compliance?

Logistics optimization in life sciences stands or falls on the sequence. The tempting sequence, first shortening routes, reducing inventory and choosing the cheapest carrier and then catching up on compliance at some point, inverts the risks. Because the EU GDP Guidelines 2013/C 343/01 require that the declared storage conditions are maintained and evidenced across the entire route. A route that has been optimized but not validated through a transport lane study is not an efficiency gain but an open risk: if the cold chain breaks, a single discarded batch costs more than the optimized route saves over months. That is why our work begins with the temperature-critical lanes and excursion management, and only on this secured foundation are network, routes and inventory optimized.

The second bottleneck lies at the handover points. Inventory, warehousing and the main leg are usually well documented; the gaps arise where the goods change hands: at a carrier that is not qualified in a GDP-compliant manner, or on the unsecured last mile for refrigerated products and high-value medicines. That is precisely where temperature control and seamless traceability break unnoticed, on which everything depends in the event of a recall. We therefore measure carrier performance through KPIs with escalation paths, secure every handover point through a quality agreement, and bring precisely those legs into validation and monitoring that slip through most easily in optimized networks.